Use of injection magnesium sulphate iv in atrial fibrillation and tachycardia
Reading File
Finding Sources
Finding Sources
Searching PubMed
magnesium sulfate atrial fibrillation rate control
Reading File
Finding Sources
Reading Article
PMID: 35503562
Reading File
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Finding Sources
I now have excellent comprehensive material. Let me compile the full answer.
IV Magnesium Sulphate in Atrial Fibrillation and Tachycardia
Mechanism of Action
Magnesium is a physiological calcium antagonist. Its antiarrhythmic effects work through several pathways:
- Inhibits calcium currents responsible for pathological early afterdepolarizations, preventing cardiac dyssynchrony
- Slows sinoatrial (SA) node activity - reduces automaticity
- Prolongs myocardial conduction time - particularly at the AV node, slowing ventricular rate in AF
- Stabilizes excitable membranes - raises the threshold for depolarization
- Cofactor in ion movement - essential for Na+/K+-ATPase activity; hypomagnesaemia worsens arrhythmia susceptibility
The key electrophysiological effect relevant to AF is AV nodal blockade, similar to calcium channel blockers but through a different mechanism. For torsades de pointes (TdP), it suppresses triggered activity (early afterdepolarizations) without necessarily shortening the QT interval. - Tintinalli's Emergency Medicine, Harriet Lane Handbook
Indications
| Arrhythmia | Role of IV MgSO4 | Evidence |
|---|---|---|
| Atrial fibrillation with rapid ventricular response (AF/RVR) | Rate control (adjunct) | Moderate - meta-analysis supports HR reduction |
| Torsades de Pointes (TdP) | First-line treatment | Strong - well-established |
| Polymorphic VT with prolonged QT | First-line treatment | Strong |
| VF/pulseless VT associated with TdP | Cardiac arrest treatment | AHA guideline supported |
| Hypomagnesaemia-associated arrhythmias | Replacement + antiarrhythmic | Strong |
1. Atrial Fibrillation with Rapid Ventricular Response
Magnesium has an adjunctive role in rate control for AF/RVR. It is not first-line but is useful when:
- Patient has concomitant hypomagnesaemia (common in critically ill, alcoholics, diuretic users)
- Standard rate control agents (beta-blockers, diltiazem) are contraindicated or inadequate
- Post-operative AF prevention/management
A 2022 systematic review and meta-analysis (5 RCTs, n=815 patients) found:
- Magnesium significantly reduced heart rate (SMD 0.34; 95% CI 0.21-0.47; P<0.001; I²=4%)
- Higher maintenance doses correlated positively with HR reduction
- Not associated with higher rates of sinus rhythm conversion (OR 1.46; P=0.29)
- No significant increase in hypotension or bradycardia (OR 2.2; P=0.22)
Hoffer et al., 2022 - Eur J Emerg Med - This is an important recent meta-analysis (PMID: 35503562)
2. Torsades de Pointes (TdP) / Polymorphic VT with Long QT
This is the primary, well-established indication for IV magnesium:
Standard management:
- Stop the offending drug (class IA, class III antiarrhythmics, QT-prolonging drugs)
- IV magnesium sulphate: 1-2 g IV - first and most important pharmacological step
- Measures to increase heart rate (IV atropine, temporary pacing, isoproterenol for refractory cases)
- Definitive treatment: ventricular pacing to prevent recurrent bursts of TdP
Note: Magnesium controls TdP without necessarily shortening the QT interval - it suppresses the triggered beats rather than normalising the substrate. - Braunwald's Heart Disease
Class IA (procainamide) and class III (amiodarone) agents are CONTRAINDICATED in TdP as they further prolong QT.
Dosing and Administration
| Setting | Dose | Rate |
|---|---|---|
| TdP / polymorphic VT (with pulse) | 1-2 g IV | Dilute in 50-100 mL NS/D5W; give over 2 min (rapid bolus) |
| Cardiac arrest (TdP associated) | 1-2 g IV | Rapid bolus |
| AF rate control (adjunct/maintenance) | 2 g IV bolus, then 1-2 g/h infusion | Bolus over 2 min; maintenance infusion |
| Paediatric (TdP/resuscitation) | 25-50 mg/kg (max 2 g) IV/IO | Over 20-60 min if pulse present; faster in arrest |
- Tintinalli's Emergency Medicine; ROSEN's Emergency Medicine; Harriet Lane Handbook (paediatric dose)
Adverse Effects
- Flushing and vasodilation - common, especially with rapid IV administration
- Hypotension - dose-related; more common with rapid infusion
- Bradycardia - can occur, especially in combination with AV nodal blocking agents
- Respiratory depression / neuromuscular blockade - at toxic serum levels (>5 mmol/L)
- Cardiac arrest - at very high levels (>12 mmol/L)
Antidote for toxicity: Calcium gluconate or calcium chloride IV
Important Contraindications / Cautions
- WPW syndrome with AF - Avoid magnesium (like other AV nodal blocking agents: adenosine, beta-blockers, calcium channel blockers, digoxin) as blocking the AV node leaves the accessory pathway open for rapid antegrade conduction, risking VF. Use procainamide or cardioversion instead. - ROSEN's Emergency Medicine
- Renal failure - magnesium accumulates; use with caution and monitor serum levels
- Concurrent AV nodal blockers - combined use increases risk of severe bradycardia/heart block
Summary Table
| Indication | IV MgSO4 Role | Standard Dose |
|---|---|---|
| AF/RVR (rate control) | Adjunct (especially if hypomagnesaemia) | 2 g bolus + 1-2 g/h infusion |
| TdP / polymorphic VT | First-line | 1-2 g rapid IV bolus |
| VF/pulseless VT in TdP | Treatment | 1-2 g rapid IV bolus |
| WPW + AF | Contraindicated | - |
Key takeaway: IV MgSO4 is the drug of choice for TdP and polymorphic VT with prolonged QT. In AF, its role is mainly adjunctive for rate control, especially in patients with hypomagnesaemia, and it does not reliably convert AF to sinus rhythm.
Sources: Tintinalli's Emergency Medicine (A Comprehensive Study); ROSEN's Emergency Medicine; Braunwald's Heart Disease 15e; Harriet Lane Handbook 23e; Hoffer et al. 2022, Eur J Emerg Med - PMID 35503562
This is a shared conversation. Sign in to Orris to start your own chat.